Vertex Pharmaceuticals Incorporated Free Cash Flow 2008–2025
Vertex Pharmaceuticals Incorporated reported $3.19B of free cash flow for fiscal 2025. That was 504.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +6.7%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $3.19B | +504.1% |
| FY 2024 | $-790.30M | -123.7% |
| FY 2023 | $3.34B | -15.0% |
| FY 2022 | $3.93B | +63.0% |
| FY 2021 | $2.41B | -19.5% |
| FY 2020 | $2.99B | +100.4% |
| FY 2019 | $1.49B | +27.2% |
| FY 2018 | $1.17B | +57.6% |
| FY 2017 | $745.52M | +315.2% |
| FY 2016 | $179.54M | +143.7% |
| FY 2015 | $-410.73M | +34.2% |
| FY 2014 | $-624.31M | -457.1% |
| FY 2013 | $-112.06M | -157.0% |
| FY 2012 | $196.70M | +80.2% |
| FY 2011 | $109.14M | +116.2% |
| FY 2010 | $-673.50M | -49.3% |
| FY 2009 | $-451.08M | -74.4% |
| FY 2008 | $-258.66M | — |
Source: Vertex Pharmaceuticals Incorporated SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open VRTX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Vertex Pharmaceuticals Incorporated reported $3.19B of free cash flow for fiscal 2025. That was 504.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +6.7%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Vertex Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVertex Pharmaceuticals Incorporated — frequently asked questions
What is Vertex Pharmaceuticals Incorporated's free cash flow?
Vertex Pharmaceuticals Incorporated (VRTX) reported free cash flow of $3.19B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Vertex Pharmaceuticals Incorporated's official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.